Duchenne muscular dystrophy: Current state and therapeutic perspectives

被引：0
|
作者：
Le Guen, Y. T. [1 ]
Le Gall, T. [1 ]
Laurent, V [1 ]
D'Arbonneau, F. [1 ]
Braun, S. [2 ]
Montier, T. [1 ,3 ]
机构：
[1] Univ Bretagne Occidentale, INSERM, Genet Genom Fonct & Biotechnol, EFS,UMR 1078, 22 Rue Camille Desmoulins,CS 93837, F-29238 Brest 3, France
[2] AFM Telethon, 1 Rue Int,BP59, F-91002 Evry, France
[3] CHRU Brest, Serv Genet Med & Biol Reprod, Ctr Reference Malad Rares Malad Neuromusculaires, F-29200 Brest, France
来源：
BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE | 2021年 / 205卷 / 05期
关键词：
Muscular Dystrophy; Duchenne; Therapeutics; Gene Therapy; GENE-THERAPY; FEMALE CARRIERS; MUSCLE; GLUCOCORTICOIDS; CHILDREN; VECTORS; IMPACT;
D O I：
10.1016/j.banm.2020.10.019
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Duchenne muscular dystrophy is one of the most frequent muscular dystrophies, with 250,000 affected people worldwide. It results from mutations occurring in the dystrophin gene, the largest known in the human genome. Despite current therapies allow for a better clinical prognosis, the life span and the quality of life of patients still remain clearly lower than those in the general population. New therapeutic approaches are currently investigated, giving new perspectives and hopes for the care of this severe disease. (C) 2021 l'Academie nationale de medecine. Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：509 / 518
页数：10
相关论文
共 50 条
  • [31] Current and Emerging Therapies for Duchenne Muscular Dystrophy
    Crone, Megan
    Mah, Jean K.
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2018, 20 (08)
  • [32] The Current State and Prospects of the Gene Therapy of Duchenne Muscular Dystrophy Worldwide and in Russia
    V. S. Baranov
    A. N. Baranov
    A. V. Zelenin
    Russian Journal of Genetics, 2001, 37 : 868 - 875
  • [33] The current state and prospects of the gene therapy of Duchenne muscular dystrophy worldwide and in Russia
    Baranov, VS
    Baranov, AN
    Zelenin, AV
    RUSSIAN JOURNAL OF GENETICS, 2001, 37 (08) : 868 - 875
  • [34] Perspectives on the advances in the pharmacotherapeutic management of Duchenne muscular dystrophy
    Kracht, Kelsie D.
    Eichorn, Nicole L.
    Berlau, Daniel J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (15) : 1701 - 1710
  • [35] Perspectives of stem cell therapy in Duchenne muscular dystrophy
    Meregalli, Mirella
    Farini, Andrea
    Belicchi, Marzia
    Parolini, Daniele
    Cassinelli, Letizia
    Razini, Paola
    Sitzia, Clementina
    Torrente, Yvan
    FEBS JOURNAL, 2013, 280 (17) : 4251 - 4262
  • [36] The perspectives and experiences of young men with Duchenne muscular dystrophy
    Player, Ben
    JOURNAL OF MEDICAL GENETICS, 2011, 48 : S96 - S96
  • [37] Therapeutic restoration of dystrophin expression in Duchenne muscular dystrophy
    Dominic J. Wells
    Journal of Muscle Research & Cell Motility, 2006, 27 : 387 - 398
  • [38] Common therapeutic advances for Duchenne muscular dystrophy (DMD)
    Salmaninejad, Arash
    Abarghan, Yousef Jafari
    Qomi, Saeed Bozorg
    Bayat, Hadi
    Yousefi, Meysam
    Azhdari, Sara
    Talebi, Samaneh
    Mojarrad, Majid
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2021, 131 (04) : 370 - 389
  • [39] THERAPEUTIC TRIAL OF ISAXONINE IN DUCHENNE MUSCULAR-DYSTROPHY
    DUBOWITZ, V
    HECKMATT, JZ
    HYDE, SA
    GABAIN, A
    MUSCLE & NERVE, 1986, 9 (05) : 270 - 270
  • [40] AdipoRon, a new therapeutic prospect for Duchenne muscular dystrophy
    Abou-Samra, Michel
    Selvais, Camille M.
    Boursereau, Raphael
    Lecompte, Sophie
    Noel, Laurence
    Brichard, Sonia M.
    JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2020, 11 (02) : 518 - 533
12345